Management of patients with biochemical recurrence after local therapy for prostate cancer

Channing J. Paller; Emmanuel S. Antonarakis; Mario A. Eisenberger; Michael A. Carducci

doi:10.1016/j.hoc.2013.08.005

Management of patients with biochemical recurrence after local therapy for prostate cancer

Channing J. Paller, Emmanuel S. Antonarakis, Mario A. Eisenberger, Michael A. Carducci

School of Medicine

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence. Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.

Original language	English (US)
Pages (from-to)	1205-1219
Number of pages	15
Journal	Hematology/Oncology Clinics of North America
Volume	27
Issue number	6
DOIs	https://doi.org/10.1016/j.hoc.2013.08.005
State	Published - Dec 2013

Keywords

Androgen-deprivation therapy
Biochemical recurrence
Hormonal therapy
Prostate cancer
Rising prostate-specific antigen

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2013.08.005

Cite this

@article{9d448ebf411845bbad37928ab3dd7d76,

title = "Management of patients with biochemical recurrence after local therapy for prostate cancer",

abstract = "Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence. Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.",

keywords = "Androgen-deprivation therapy, Biochemical recurrence, Hormonal therapy, Prostate cancer, Rising prostate-specific antigen",

author = "Paller, {Channing J.} and Antonarakis, {Emmanuel S.} and Eisenberger, {Mario A.} and Carducci, {Michael A.}",

year = "2013",

month = dec,

doi = "10.1016/j.hoc.2013.08.005",

language = "English (US)",

volume = "27",

pages = "1205--1219",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders",

number = "6",

}

TY - JOUR

T1 - Management of patients with biochemical recurrence after local therapy for prostate cancer

AU - Paller, Channing J.

AU - Antonarakis, Emmanuel S.

AU - Eisenberger, Mario A.

AU - Carducci, Michael A.

PY - 2013/12

Y1 - 2013/12

N2 - Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence. Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.

AB - Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence. Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.

KW - Androgen-deprivation therapy

KW - Biochemical recurrence

KW - Hormonal therapy

KW - Prostate cancer

KW - Rising prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=84887016282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887016282&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2013.08.005

DO - 10.1016/j.hoc.2013.08.005

M3 - Review article

C2 - 24188259

AN - SCOPUS:84887016282

SN - 0889-8588

VL - 27

SP - 1205

EP - 1219

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 6

ER -

Management of patients with biochemical recurrence after local therapy for prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this